RHHBY
Roche Holdings AG ADR

3,579
Mkt Cap
$262.55B
Volume
2.78M
52W High
$49.20
52W Low
$34.10
PE Ratio
27.77
RHHBY Fundamentals
Price
$47.59
Prev Close
$49.01
Open
$48.46
50D MA
$43.51
Beta
0.32
Avg. Volume
1.77M
EPS (Annual)
$1.47
P/B
8.41
Rev/Employee
$665,306.28
Loading...
Loading...
News
all
press releases
The Zacks Analyst Blog Highlights Alphabet, Roche, RTX, Crawford United and C&F Financial
Alphabet, Roche, RTX, Crawford United and C&F Financial are featured as analysts highlight strong momentum across AI, biopharma, aerospace and micro-cap industrials.
Zacks·2h ago
News Placeholder
More News
News Placeholder
Top Stock Reports for Alphabet, Roche & RTX
Alphabet gains momentum as AI-driven growth in Cloud, Search and YouTube fuels rising customer adoption and revenue strength.
Zacks·13h ago
News Placeholder
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
Zacks·5d ago
News Placeholder
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
Zacks·7d ago
News Placeholder
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.
Stocktwits·7d ago
News Placeholder
Never Mind the Cloudflare System Issues, Here’s the Morning Market Update
DENVER, Colo., Nov 18, 2025 (247marketnews.com)- Roche Group’s (OTCQX:RHHBY) Genentech, reported positive Phase III results... The post Never Mind the Cloudflare System Issues, Here’s the Morning Market Update appeared first on 24/7 MarketNews.
24-7 Market News·7d ago
News Placeholder
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
Zacks·8d ago
News Placeholder
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Zacks·18d ago
News Placeholder
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Zacks·20d ago
News Placeholder
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues. Stock falls.
Zacks·20d ago

Latest RHHBY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.